NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Updated: Feb 4
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Sponsor
ClinicalTrials.gov Identifier: NCT05427812
Official Title: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma
First Posted : June 22, 2022
Click here to see details on ClinicalTrials.gov
Drug: ISB 1442 SC injection escalating doses
Drug: ISB 1442 SC injection at RP2D
Anti-CD38/Anti-CD47 Bispecific Antibody ISB 1442 (Code C188360)
Anti-CD38/Anti-CD47 Bispecific Antibody ISB 1442
Anti-CD38/CD47 Bispecific Antibody ISB 1442
CD38 x CD47 Bispecific Antibody ISB 1442
ISB 1442
ISB-1442
ISB1442
Locations
United States, New York
Australia, New South Wales
Australia, Queensland
Australia, Victoria
Australia, Western Australia